Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Mirzotamab clezutoclax |
Synonyms | |
Therapy Description |
Mirzotamab clezutoclax (ABBV-155) is an antibody-drug conjugate (ADC) consisting of a BCL-XL inhibitor linked to a monoclonal antibody targeted against CD276 (B7H3), which may have antitumor activity (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 3015). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Mirzotamab clezutoclax | ABBV-155|ABBV 155|ABBV155 | BCL-XL inhibitor 14 CD276 Antibody 16 | Mirzotamab clezutoclax (ABBV-155) is an antibody-drug conjugate (ADC) consisting of a BCL-XL inhibitor linked to a monoclonal antibody targeted against CD276 (B7H3), which may have antitumor activity (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 3015). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03595059 | Phase I | Docetaxel + Mirzotamab clezutoclax Mirzotamab clezutoclax + Paclitaxel Mirzotamab clezutoclax | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors | Active, not recruiting | USA | NLD | ISR | ESP | CAN | AUS | 4 |